Avalon GloboCare (NASDAQ:ALBT – Get Rating) is one of 59 publicly-traded companies in the "Management consulting services" industry, but how does it contrast to its rivals? We will compare Avalon GloboCare to similar businesses based on the strength of its dividends, analyst recommendations, valuation, profitability, risk, earnings and institutional ownership.
Institutional and Insider Ownership
0.9% of Avalon GloboCare shares are held by institutional investors. Comparatively, 42.3% of shares of all "Management consulting services" companies are held by institutional investors. 64.0% of Avalon GloboCare shares are held by insiders. Comparatively, 28.0% of shares of all "Management consulting services" companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Get
Avalon GloboCare alerts:
Analyst Ratings
This is a summary of current recommendations and price targets for Avalon GloboCare and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| Avalon GloboCare | 0 | 0 | 0 | 0 | N/A |
| Avalon GloboCare Competitors | 54 | 447 | 961 | 15 | 2.63 |
As a group, "Management consulting services" companies have a potential upside of 46.83%. Given Avalon GloboCare's rivals higher probable upside, analysts plainly believe Avalon GloboCare has less favorable growth aspects than its rivals.
Earnings and Valuation
This table compares Avalon GloboCare and its rivals top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio |
| Avalon GloboCare | $1.39 million | -$9.09 million | -2.57 |
| Avalon GloboCare Competitors | $1.57 billion | $111.52 million | 13.98 |
Avalon GloboCare's rivals have higher revenue and earnings than Avalon GloboCare. Avalon GloboCare is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
Avalon GloboCare has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Avalon GloboCare's rivals have a beta of 1.76, suggesting that their average stock price is 76% more volatile than the S&P 500.
Profitability
This table compares Avalon GloboCare and its rivals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| Avalon GloboCare | -955.48% | -460.58% | -97.43% |
| Avalon GloboCare Competitors | -58.82% | -81.78% | -7.60% |
Summary
Avalon GloboCare rivals beat Avalon GloboCare on 9 of the 10 factors compared.
About Avalon GloboCare
(Get Rating)
Avalon GloboCare Corp. is a holding company, which engages in the development of biotechnology and the provision of healthcare services. It operates through the following segments: Real Property Operating, Medical Related Consulting Services, and Development Services & Sales of Developed Products. It offers regenerative medicine, cell-based immunotherapy, exosome technology, and rehabilitation medicine through Avalon Cell and Avalon Rehab platforms. The company was founded on July 28, 2014 and is headquartered in Freehold, NJ.
Receive News & Ratings for Avalon GloboCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalon GloboCare and related companies with MarketBeat.com's FREE daily email newsletter.
